CT
BIB icon

CMT Trading’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

CMT Trading’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,071
Closed -$233K – 20
2018
Q2 		$233K Buy
+4,071
New +$222K 1.27% 12
2018
Q1 		– Sell
-5,000
Closed -$280K – 11
2017
Q4 		$280K Buy
+5,000
New +$282K 0.38% 14
2016
Q3 		– Sell
-14,707
Closed -$571K – 38
2016
Q2 		$571K Buy
+14,707
New +$634K 0.97% 21

Other funds holding BIB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CMT Trading's BIB Position: Q3 2018 in Review

CMT Trading sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2018, closing a stake of 4,071 shares — an estimated $233K sold.

CMT Trading first reported a position in BIB in Q2 2016 and held it in 3 quarters. The position peaked at $571K in Q2 2016. 41 funds tracked by Wall St. Rank hold BIB as of Q3 2018.

  • CMT Trading reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2018 after selling out during the quarter.
  • CMT Trading sold 4,071 ProShares Ultra NASDAQ Biotechnology shares in Q3 2018, an estimated $233K.
  • CMT Trading first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2016 and held it in 3 quarters.
  • CMT Trading's ProShares Ultra NASDAQ Biotechnology position peaked at $571K in Q2 2016.
  • 41 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2018.

Based on CMT Trading's 13F filing for Q3 2018, filed 14 Nov 2018.